Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2009 Nov;18(9):1195-205.
doi: 10.1007/s11136-009-9539-2. Epub 2009 Sep 24.

The comparative responsiveness of the EQ-5D and SF-6D to change in patients with inflammatory arthritis

M J Harrison  1 , L M Davies, N J Bansback, M J McCoy, S M M Verstappen, K Watson, D P M Symmons; British Society for Rheumatology Biologics Register Control Centre Consortium
Collaborators, Affiliations
Comparative Study

The comparative responsiveness of the EQ-5D and SF-6D to change in patients with inflammatory arthritis

M J Harrison et al. Qual Life Res. 2009 Nov.

Abstract

Purpose: Comparative evidence regarding the responsiveness of the EQ-5D and SF-6D in arthritis patients is conflicting and insufficient across the range of disease severity. We examined the comparative responsiveness of the EQ-5D and SF-6D in cohorts of patients with early inflammatory disease through to severe rheumatoid arthritis (RA).

Methods: Responsiveness was tested using the effect size (ES) and standardised response mean (SRM). Correlation of change in EQ-5D and SF-6D with disease specific measures was tested using Pearson correlations and the Steiger's Z test. Treatment response and self-reported change were used as anchors of important change.

Results: The EQ-5D was more responsive to deterioration (ES ratio (EQ-5D/SF-6D): 1.6-3.0) and the SF-6D more responsive to improvement (ES ratio (SF-6D/EQ-5D): 1.1-1.8) in health. The SF-6D did not respond well to deterioration in patients with established severe RA (ES and SRM 0.08). The EQ-5D provided larger absolute mean change estimates but with greater variance compared to the SF-6D.

Conclusions: The comparative responsiveness of the EQ-5D and SF-6D differs according to the direction of change. The level of mean change of the EQ-5D relative to the SF-6D has implications for cost-effectiveness analysis. Use of the SF-6D in patients with severe progressive disease may be inappropriate.

PubMed Disclaimer

References

    1. None
    2. Drummond, M. F., Sculpher, M. J., Torrance, G. W., O’Brien, B. J., & Stoddart, G. L. (2005). Methods for the economic evaluation of health care programmes (3rd ed.). Oxford: Oxford University Press.
    1. None
    2. National Institute for Health and Clinical Excellence. (2005). A guide to NICE. London: National Institute for Clinical Excellence.
    1. Ontario Ministry of Health and Long-Term Care. (2007). Ontario guidelines for economic analysis of pharmaceutical products. Internet 2004 August [cited 2007 Jan 31];Available from: URL: http://www.health.gov.on.ca/english/providers/pub/drugs/economic/economi....
    1. None
    2. Sullivan, S. D., Lyles, A., Luce, B., & Grigar, J. (2001). AMCP guidance for submission of clinical and economic evaluation data to support formulary listing in U.S. health plans and pharmacy benefits management organizations. Journal of Managed Care Pharmacy,7(4), 272–282.
    1. NICE. (2004). Guide to the methods of technology appraisal. London: National Institute for Clinical Excellence. Ref Type: Pamphlet.

Publication types